No products in the cart.
SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes
1. SGLT2 inhibitors reduced the risk of kidney disease progression by 37% overall, with comparable effects in patients with and ...
Tag: eGFR
Adjuvant erlotinib increased overall survival when compared to chemotherapy in stage IIIA EGFR-mutant non-small cell lung cancer
1. Erlotinib showed an overall survival benefit and improved 5-year survival rates when compared to chemotherapy. 2. Disease-free survival was ...
Discrepancies exist between measured and estimated glomerular filtration rate
1. There are significant differences between measured and estimated glomerular filtration rate (mGFR and eGFR) at the individual patient level. ...
#VisualAbstract: Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial
1. This randomized controlled trial found that high dose methylprednisolone for 6-9 months reduced rates of significantly declining kidney function, ...
Effectiveness of sacubitril-valsartan in post-myocardial infarction management
1. In patients with acute myocardial infarction, Sacubitril-valsartan was not associated with a significantly lower incidence of death from cardiovascular ...
Empaglifozin reduces death in heart failure patients with preserved ejection fraction
1. Empaglifozin treatment was shown to have reduced rates of cardiovascular death or hospitalization in patients with heart failure and ...
Mobocertinib is a tolerable and possible treatment option for patients with EGFR exon 20 insertion mutated advanced non-small-cell lung cancer
1. Overall response rate was 28% and 35% in the platinum pretreated cohort (PPP) and 25% and 32% in the ...
#VisualAbstract: Oxygenated hypothermic perfusion reduces post-kidney transplant complications
1. Oxygenated hypothermic machine perfusion (HMPO2) of kidneys donated after circulatory death was associated with fewer severe complications and lower ...
